About | Free Trial

Last Update

2015-09-14T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong David Enscore?

Dr. David Enscore J. PhD

Principal Scientist

4P Therapeutics LLC

HQ Phone: (770) 263-1900

4P Therapeutics LLC

680 Engineering Drive Suite 150

Norcross, Georgia 30092

United States

Company Description

4P Therapeutics is a private company focused on the research and development of novel drug delivery technologies and therapeutics. 4P develops products that meet the needs of patients, physicians and payers. The company has capabilities for developing pha... more

Find other employees at this company (2)

Background Information

Employment History

Senior Vice President of Research and Development
Altea Therapeutics Corporation

Named Interim President
Spherics , Inc.

Education

BS

North Carolina State University

Ph.D.

PhD
Chemical Engineering
North Carolina State University

Web References (23 Total References)


Leadership - 4P THERAPEUTICS - Transdermal Research and Development

www.4ptherapeutics.com [cached]

David Enscore, Ph.D. - Principal Scientist

David J. Enscore advises 4P Therapeutics technology selection, product design goals, and analyzes results from product development studies. Over the last several years, he has provided product development direction to the pharmaceutical and medical device industries on a consulting basis. His focus is on controlled drug delivery products in general with a strong emphasis on transdermal drug delivery systems. In a consulting role, he served as Interim Vice President of R&D at Micell Technologies, a company developing a sirolimus eluting, bioabsorbable polymer coated coronary artery stent.
He has served as an expert witness in several patent litigation cases involving transdermal technology. Prior to starting his consulting business, Dr. Enscore was Senior Vice President, Product Research and Development at Altea Therapeutics and was responsible for all product development activities including pharmaceutical science, engineering, clinical R&D, quality assurance, and regulatory affairs. Before joining Altea Therapeutics, he held senior R&D positions at Spherics, Incorporated, an advanced oral drug delivery company and Focal, Incorporated, a company that developed resorbable tissue sealants.
Prior to this, Dr. Enscore worked extensively in transdermal drug delivery, in various scientific and management positions, at Alza Corporation. At Alza, he lead the development of Nicoderm® CQ (transdermal nicotine), the second generation testosterone transdermal system (Testoderm® TTS), and the Actisite® tetracycline periodontal fiber. He has been granted 25 U.S. patents in controlled drug delivery and biodegrabable polymers. Dr. Enscore received a BS and a PhD in Chemical Engineering, with a minor in Polymer Science, from North Carolina State University.


David Enscore, ...

www.4ptherapeutics.com [cached]

David Enscore, Ph.D. Senior Scientific Advisor

David J. Enscore advises 4P Therapeutics technology selection, product design goals, and analyzes results from product development studies. Over the last several years, he has provided product development direction to the pharmaceutical and medical device industries on a consulting basis. His focus is on controlled drug delivery products in general with a strong emphasis on transdermal drug delivery systems. In a consulting role, he served as Interim Vice President of R&D at Micell Technologies, a company developing a sirolimus eluting, bioabsorbable polymer coated coronary artery stent. He has served as an expert witness in several patent litigation cases involving transdermal technology. Prior to starting his consulting business, Dr. Enscore was Senior Vice President, Product Research and Development at Altea Therapeutics and was responsible for all product development activities including pharmaceutical science, engineering, clinical R&D, quality assurance, and regulatory affairs. Before joining Altea Therapeutics, he held senior R&D positions at Spherics, Incorporated, an advanced oral drug delivery company and Focal, Incorporated, a company that developed resorbable tissue sealants. Prior to this, Dr. Enscore worked extensively in transdermal drug delivery, in various scientific and management positions, at Alza Corporation. At Alza, he lead the development of Nicoderm® CQ (transdermal nicotine), the second generation testosterone transdermal system (Testoderm® TTS), and the Actisite® tetracycline periodontal fiber. He has been granted 25 U.S. patents in controlled drug delivery and biodegrabable polymers. Dr. Enscore received a BS and a PhD in Chemical Engineering, with a minor in Polymer Science, from North Carolina State University.


About Altea Therapeutics

www.alteatherapeutics.com [cached]

David EnscoreSenior Vice PresidentProduct Research & Development


POD Holding

www.podholding.com [cached]

David J. Enscore, Ph.D., Named Interim President of Spherics, Inc.October 2, 2002, Lincoln, Rhode Island - Spherics, Inc. today announced that David J. Enscore, Ph.D. has been named Interim President, ...


David J. Enscore, Ph.D., ...

www.ibclifesciencesinfo.com [cached]

David J. Enscore, Ph.D., Altea Therapeutics Corporation

Similar Profiles

Other People with this Name

Other people with the name Enscore

Russell Enscore
Centers for Disease Control and Prevention

Emory Enscore
Kecoughtan High School

Susan Enscore
Army Corps

Michael Enscore
Home Builders Association of Winston-Salem Inc

Emily Enscore
Office Depot Inc

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory